{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:54:41Z","timestamp":1774414481278,"version":"3.50.1"},"reference-count":126,"publisher":"Bentham Science Publishers Ltd.","issue":"41","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,3,20]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Pseudophakic cystoid macular edema (PCME) remains one of the most common visionthreatening complication of phacoemulsification cataract surgery (PCS). Pharmacological therapy is the current mainstay of both prophylaxis, and treatment of PCME in patients undergoing PCS. We aimed to review pharmacological treatment options for PCME, which primarily include topical steroids, topical nonsteroidal antiinflammatory drugs (NSAIDS), periocular and intravitreal steroids, as well as anti-vascular endothelial growth factor therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>The PubMed and Web Of Science web platforms were used to find relevant studies using the following keywords: cataract surgery, phacoemulsification, cystoid macular edema, and pseudophakic cystoid macular edema. Of articles retrieved by this method, all publications in English and abstracts of non-English publications were reviewed. Other studies were also considered as a potential source of information when referenced in relevant articles. The search revealed 193 publications. Finally 82 articles dated from 1974 to 2018 were assessed as significant and analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Based on the current literature, we found that corticosteroids remain the mainstay of PCME prophylaxis in uncomplicated cataract surgery, while it is still unclear if NSAID can offer additional benefits. In patients at risk for PCME development, periocular subconjunctival injection of triamcinolone acetonide may prevent PCME development. For PCME treatment the authors recommend a stepwise therapy: initial topical steroids and adjuvant NSAIDs, followed by additional posterior sub-Tenon or retrobulbar corticosteroids in moderate PCME, and intravitreal corticosteroids in recalcitrant PCME. Intravitreal anti-vascular endothelial growth factor agents may be considered in patients unresponsive to steroid therapy at risk of elevated intraocular pressure, and with comorbid macular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Therapy with topical corticosteroids and NSAIDs is the mainstay of PCME prophylaxis and treatment, however, periocular and intravitreal steroids should be considered in refractory cases.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612825666190206104524","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T06:13:20Z","timestamp":1553235200000},"page":"4896-4902","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The Role of Steroids and NSAIDs in Prevention and Treatment of Postsurgical Cystoid Macular Edema"],"prefix":"10.2174","volume":"24","author":[{"given":"Andrzej","family":"Grzybowski","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Warmia and Mazury, Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Kanclerz","sequence":"additional","affiliation":[{"name":"Private Practice, Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"Brown D.M.","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study.","journal-title":"Ophthalmology"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archopht.125.11.1460","volume":"125","author":"Chang T.S.","year":"2007","unstructured":"Chang TS, Bressler NM, Fine JT. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.","journal-title":"Arch Ophthalmol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"Heier J.S.","year":"2012","unstructured":"Heier JS, Brown DM, Chong V. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration.","journal-title":"Ophthalmology"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000446027","volume":"236","author":"Holz F.G.","year":"2016","unstructured":"Holz FG, Tufail A, Leveziel N. Ranibizumab in myopic choroidal neovascularization: a subgroup analysis by ethnicity, age, and ocular characteristics in RADIANCE.","journal-title":"Ophthalmologica"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Ikuno Y.","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study.","journal-title":"Ophthalmology"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"Schmidt-Erfurth U.","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).","journal-title":"Br J Ophthalmol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","volume":"63","author":"Ohno-Matsui K.","year":"2018","unstructured":"Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia.","journal-title":"Prog Retin Eye Res"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1097\/IAE.0000000000001744","volume":"38","author":"Lai T.Y.","year":"2018","unstructured":"Lai TY, Staurenghi G, Lanzetta P. Efficacy and safety of ranibizumab for the treatment of Choroidal Neovascularization due to uncommon cause: twelve-month results of the MINERVA Study.","journal-title":"Retina"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ajo.2007.02.039","volume":"143","author":"Chan W.M.","year":"2007","unstructured":"Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.","journal-title":"Am J Ophthalmol"},{"key":"ref=10","first-page":"479","volume":"6","author":"Lai T.Y.Y.","year":"2017","unstructured":"Lai TYY, Cheung CMG, Mieler WF. Ophthalmic application of anti-VEGF therapy.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"Li X.","year":"2014","unstructured":"Li X, Xu G, Wang Y. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.","journal-title":"Ophthalmology"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","volume":"26","author":"Spaide R.F.","year":"2006","unstructured":"Spaide RF, Laud K, Fine HF. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.","journal-title":"Retina"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","volume":"26","author":"Lai T.Y.","year":"2012","unstructured":"Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.","journal-title":"Eye (Lond)"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.22608\/APO.2017416","volume":"6","author":"Singh S.R.","year":"2017","unstructured":"Singh SR, Dogra A, Stewart M. Intravitreal ziv-aflibercept: clinical effects and economic impact.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ajo.2013.04.040","volume":"156","author":"Baxter S.L.","year":"2013","unstructured":"Baxter SL, Pistilli M, Pujari SS. Risk of choroidal neovascularization among the uveitides.","journal-title":"Am J Ophthalmol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/bjo.2009.177279","volume":"95","author":"Gulati N.","year":"2011","unstructured":"Gulati N, Forooghian F, Lieberman R, Jabs DA. Vascular endothelial growth factor inhibition in uveitis: a systematic review.","journal-title":"Br J Ophthalmol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/archopht.116.11.1456","volume":"116","author":"Dees C.","year":"1998","unstructured":"Dees C, Arnold JJ, Forrester JV, Dick AD. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis.","journal-title":"Arch Ophthalmol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"450428","DOI":"10.1155\/2014\/450428","volume":"2014","author":"D\u2019Ambrosio E.","year":"2014","unstructured":"D\u2019Ambrosio E, Tortorella P, Iannetti L. Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy.","journal-title":"J Ophthalmol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/bjophthalmol-2016-309994","volume":"101","author":"Braimah I.","year":"2017","unstructured":"Braimah I, Stewart M, Videkar C. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.","journal-title":"Br J Ophthalmol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2147\/OPTH.S34294","volume":"6","author":"Mansour A.","year":"2012","unstructured":"Mansour A, Mackensen F, Khairallah M. Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.","journal-title":"Clin Ophthalmol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/IAE.0b013e3182003ca8","volume":"31","author":"Rouvas A.","year":"2011","unstructured":"Rouvas A, Petrou P, Douvali M. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.","journal-title":"Retina"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2006.10.047","volume":"144","author":"Gerstenblith A.T.","year":"2007","unstructured":"Gerstenblith AT, Thorne JE, Sobrin L. Punctate inner choroidopathy: a survey analysis of 77 persons.","journal-title":"Ophthalmology"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archopht.120.7.996","volume":"120","author":"Brueggeman R.M.","year":"2002","unstructured":"Brueggeman RM, Noffke AS, Jampol LM. Resolution of punctate inner choroidopathy lesions with oral prednisone therapy.","journal-title":"Arch Ophthalmol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12348-011-0050-x","volume":"2","author":"Pachydaki S.I.","year":"2012","unstructured":"Pachydaki SI, Jakobiec FA, Bhat P. Surgical management and ultrastructural study of choroidal neovascularization in punctate inner choroidopathy after bevacizumab.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e31815e9339","volume":"28","author":"Chan W.M.","year":"2008","unstructured":"Chan WM, Lai TY, Lau TT. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series.","journal-title":"Retina"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/IAE.0b013e318242b9da","volume":"32","author":"Zhang H.","year":"2012","unstructured":"Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial.","journal-title":"Retina"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/IAE.0b013e3181d374dc","volume":"30","author":"Menezo V.","year":"2010","unstructured":"Menezo V, Cuthbertson F, Downes SM. Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy.","journal-title":"Retina"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08820538.2010.541322","volume":"26","author":"Mangat S.S.","year":"2011","unstructured":"Mangat SS, Ramasamy B, Prasad S. Resolution of choroidal neovascularization secondary to punctate inner choroidopathy (PIC) with intravitreal anti-VEGF agents: a case series.","journal-title":"Semin Ophthalmol"},{"key":"ref=29","first-page":"1585803","volume":"2018","author":"Wu W.","year":"2018","unstructured":"Wu W, Li S, Xu H. Treatment of punctate inner choroidopathy with choroidal neovascularization using corticosteroid and intravitreal ranibizumab.","journal-title":"BioMed Res Int"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12886-017-0481-8","volume":"17","author":"Peng Y.","year":"2017","unstructured":"Peng Y, Zhang X, Mi L, Liu B, Zuo C, Li M, Wen F. Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy.","journal-title":"BMC Ophthalmol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0161-6420(96)30561-7","volume":"103","author":"Brown J.","year":"1996","unstructured":"Brown J, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome.","journal-title":"Ophthalmology"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/IAE.0b013e318275397c","volume":"33","author":"Parodi M.B.","year":"2013","unstructured":"Parodi MB, Iacono P, Mansour A. Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis.","journal-title":"Retina"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/IAE.0b013e318187aff9","volume":"29","author":"Fine H.F.","year":"2009","unstructured":"Fine HF, Zhitomirsky I, Freund KB. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.","journal-title":"Retina"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/archophthalmol.2010.205","volume":"128","author":"Parodi M.B.","year":"2010","unstructured":"Parodi MB, Iacono P, Kontadakis DS. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.","journal-title":"Arch Ophthalmol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s004170050342","volume":"237","author":"Lertsumitkul S.","year":"1999","unstructured":"Lertsumitkul S, Whitcup SM, Nussenblatt RB, Chan CC. Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"747648","DOI":"10.1155\/2011\/747648","volume":"2011","author":"Kolomeyer A.M.","year":"2011","unstructured":"Kolomeyer AM, Roy MS, Chu DS. The use of intravitreal ranibizumab for choroidal neovascularization associated with Vogt-Koyanagi-Harada syndrome.","journal-title":"Case Rep Med"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3129\/i09-144","volume":"44","author":"Raffa L.","year":"2009","unstructured":"Raffa L, Bawazeer A. Intravitreal bevacizumab injection in a 14-year-old Vogt-Koyanagi-Harada patient with choroidal neovascular membrane.","journal-title":"Can J Ophthalmol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10384-008-0600-4","volume":"53","author":"Wu L.","year":"2009","unstructured":"Wu L, Evans T, Saravia M. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome.","journal-title":"Jpn J Ophthalmol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.jcjo.2012.03.032","volume":"47","author":"Balaskas K.","year":"2012","unstructured":"Balaskas K, Ur Rehman S, D\u2019Souza Y. Long-term ranibizumab treatment for choroidal neovascularization secondary to serpiginous choroiditis.","journal-title":"Can J Ophthalmol"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000320011","volume":"46","author":"Parodi M.","year":"2010","unstructured":"Parodi M, Iacono P, Verbraak FD, Bandello F. Antivascular endothelial growth factors for inflammatory chorioretinal disorders.","journal-title":"Dev Ophthalmol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MCP.0000000000000409","volume":"23","author":"Yang S.J.","year":"2017","unstructured":"Yang SJ, Salek S, Rosenbaum JT. Ocular sarcoidosis: new diagnostic modalities and treatment.","journal-title":"Curr Opin Pulm Med"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bjo.66.8.530","volume":"66","author":"Hoogstede H.A.","year":"1982","unstructured":"Hoogstede HA, Copper AC. A case of macular subretinal neovascularisation in chronic uveitis probably caused by sarcoidosis.","journal-title":"Br J Ophthalmol"},{"key":"ref=43","first-page":"2014","author":"Khatib T.","year":"2014","unstructured":"Khatib T, Hughes PW, Burton BJ. Unilateral choroidal granulomas complicated by choroidal neovascular membrane treated successfully with intravitreal triamcinolone in a patient with sarcoidosis.","journal-title":"BMJ Case Rep"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1755-3768.2008.01208.x","volume":"87","author":"Kurup S.","year":"2009","unstructured":"Kurup S, Lew J, Byrnes G. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization.","journal-title":"Acta Ophthalmol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.5301\/ejo.5000759","volume":"26","author":"Querques L.","year":"2016","unstructured":"Querques L, Querques G, Miserocchi E. Intravitreal aflibercept for choroidal neovascularization in ocular sarcoidosis.","journal-title":"Eur J Ophthalmol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1111\/j.1755-3768.2009.01590.x","volume":"88","author":"Shah S.P.","year":"2010","unstructured":"Shah SP, Hubschman JP, Bourges JL. Limited long\u2010term efficacy of intravitreous anti\u2010VEGF pharmacotherapy in sarcoidosis complicated by peripapillary choroidal neovascular membrane.","journal-title":"Acta Ophthalmol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0002-9394(81)90283-X","volume":"91","author":"Fine S.","year":"1981","unstructured":"Fine S, Owens S, Haller J. Choroidal neovascularization as a late complication of ocular toxoplasmosis.","journal-title":"Am J Ophthalmol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/08820538.2013.838278","volume":"30","author":"Kianersi F.","year":"2013","unstructured":"Kianersi F, Naderi Beni A. Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series.","journal-title":"Semin Ophthalmol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4103\/0301-4738.82005","volume":"59","author":"Shah N.J.","year":"2011","unstructured":"Shah NJ, Shah UN. Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis.","journal-title":"Indian J Ophthalmol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2147\/OPTH.S132923","volume":"11","author":"Korol A.R.","year":"2017","unstructured":"Korol AR, Zborovska O, Kustryn T. Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study.","journal-title":"Clin Ophthalmol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICB.0b013e3181ff09ae","volume":"5","author":"Lin C.J.","year":"2011","unstructured":"Lin CJ, Chen SN, Hwang JF, Hu PS. Successful treatment of toxoplasmosis-associated choroidal neovascular lesions with bevacizumab and antiparasitic therapy.","journal-title":"Retin Cases Brief Rep"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0301-4738.73728","volume":"59","author":"Rishi P.","year":"2011","unstructured":"Rishi P, Venkataraman A, Rishi E. Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis.","journal-title":"Indian J Ophthalmol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1607-551X(09)70566-2","volume":"25","author":"Sheu S.J.","year":"2009","unstructured":"Sheu SJ. Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to endogenous endophthalmitis.","journal-title":"Kaohsiung J Med Sci"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/ICB.0b013e3181e1ed1e","volume":"5","author":"Fecko A.M.","year":"2011","unstructured":"Fecko AM, Ho LY, Walsh MK, Williams GA. Intravitreal bevacizumab and ranibizumab for choroidal neovascularization secondary to endogenous endophthalmitis.","journal-title":"Retin Cases Brief Rep"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000441694","volume":"6","author":"Hohberger B.","year":"2015","unstructured":"Hohberger B, Rudolph M, Bergua A. Choroidal neovascularization associated with punctate inner choroidopathy: combination of intravitreal anti-VEGF and systemic immunosuppressive therapy.","journal-title":"Case Rep Ophthalmol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/aos.12940","volume":"94","author":"Schatz P.","year":"2016","unstructured":"Schatz P, Skarin A, Lavaque AJ. Preservation of macular structure and function after intravitreal aflibercept for choroidal neovascularization associated with serpiginous choroiditis.","journal-title":"Acta Ophthalmol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1755-3768.2010.02046.x","volume":"89","author":"Juli\u00e1n K.","year":"2011","unstructured":"Juli\u00e1n K, Terrada C, Fardeau C. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results.","journal-title":"Acta Ophthalmol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1755-3768.2008.01319.x","volume":"87","author":"Guthoff R.","year":"2009","unstructured":"Guthoff R, Goebel W. Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis.","journal-title":"Acta Ophthalmol"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"Daruich A.","year":"2015","unstructured":"Daruich A, Matet A, Dirani A. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis.","journal-title":"Prog Retin Eye Res"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/IAE.0b013e3182680a66","volume":"32","author":"Fung A.T.","year":"2012","unstructured":"Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration.","journal-title":"Retina"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0161-6420(96)30386-2","volume":"103","author":"Spaide R.F.","year":"1996","unstructured":"Spaide RF, Campeas L, Haas A. Central serous chorioretinopathy in younger and older adults.","journal-title":"Ophthalmology"},{"key":"ref=62","first-page":"8","volume":"2018","author":"Kang H.","year":"2018","unstructured":"Kang H, Byeon SH, Kim SS. Combining en face optical coherence tomography angiography with structural optical coherence tomography and blood flow analysis for detecting choroidal neovascular complexes in pigment epithelial detachments.","journal-title":"Retina"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"Pang C.E.","year":"2015","unstructured":"Pang CE, Freund KB. Pachychoroid neovasculopathy.","journal-title":"Retina"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0002-9394(00)00395-0","volume":"130","author":"Cooper B.A.","year":"2000","unstructured":"Cooper BA, Thomas MA. Submacular surgery to remove choroidal neovascularization associated with central serous chorioretinopathy.","journal-title":"Am J Ophthalmol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archopht.122.1.37","volume":"122","author":"Ergun E.","year":"2004","unstructured":"Ergun E, Tittl M, Stur M. Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy.","journal-title":"Arch Ophthalmol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0002-9394(03)00462-8","volume":"136","author":"Chan W.M.","year":"2003","unstructured":"Chan WM, Lam DS, Lai TY. Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin.","journal-title":"Am J Ophthalmol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1097\/IAE.0000000000000655","volume":"35","author":"Chhablani J.","year":"2015","unstructured":"Chhablani J, Kozak I, Pichi F. Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents.","journal-title":"Retina"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/eye.2016.41","volume":"30","author":"Smretschnig E.","year":"2016","unstructured":"Smretschnig E, Hagen S, Glittenberg C. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.","journal-title":"Eye (Lond)"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0039-6257(82)90158-8","volume":"26","author":"Clarkson J.","year":"1982","unstructured":"Clarkson J, Altman R. Angioid streaks.","journal-title":"Surv Ophthalmol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00006982-199701000-00003","volume":"17","author":"Pece A.","year":"1997","unstructured":"Pece A, Avanza P, Galli L, Brancato R. Laser photocoagulation of choroidal neovascularization in angioid streaks.","journal-title":"Retina"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2005.02.011","volume":"112","author":"Browning A.C.","year":"2005","unstructured":"Browning AC, Chung AK, Ghanchi F. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks one-year results of a prospective case series.","journal-title":"Ophthalmology"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9394(00)00809-6","volume":"131","author":"Roth D.B.","year":"2001","unstructured":"Roth DB, Estafanous M, Lewis H. Macular translocation for subfoveal choroidal neovascularization in angioid streaks.","journal-title":"Am J Ophthalmol"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/IAE.0b013e3182914d2b","volume":"33","author":"Gliem M.","year":"2013","unstructured":"Gliem M, Finger RP, Fimmers R. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review.","journal-title":"Retina"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ajo.2010.06.004","volume":"150","author":"Mimoun G.","year":"2010","unstructured":"Mimoun G, Tilleul J, Leys A, Coscas G. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks.","journal-title":"Am J Ophthalmol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ajo.2016.03.017","volume":"165","author":"Iacono P.","year":"2016","unstructured":"Iacono P, Battaglia Parodi M. Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks: 3-year follow-up study.","journal-title":"Am J Ophthalmol"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/IAE.0000000000000745","volume":"36","author":"Tilleul J.","year":"2016","unstructured":"Tilleul J, Mimoun G, Querques G. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks: four-year follow-up.","journal-title":"Retina"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"","year":"2012","unstructured":". Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration two-year results.","journal-title":"Ophthalmology"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/IAE.0b013e318207d1dc","volume":"31","author":"Finger R.P.","year":"2011","unstructured":"Finger RP, Charbel Issa P, Schmitz-Valckenberg S. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.","journal-title":"Retina"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ajo.2009.04.026","volume":"148","author":"Sawa M.","year":"2009","unstructured":"Sawa M, Gomi F, Tsujikawa M. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.","journal-title":"Am J Ophthalmol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/IAE.0000000000000605","volume":"35","author":"Alag\u00f6z C.","year":"2015","unstructured":"Alag\u00f6z C, Alag\u00f6z N, \u00d6zkaya A. Intravitreal bevacizumab in the treatment of choroidal neovascular membrane due to angioid streaks.","journal-title":"Retina"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/0974-9233.134686","volume":"21","author":"Alameddine R.M.","year":"2014","unstructured":"Alameddine RM, Mansour AM, Kahtani E. Review of choroidal osteomas.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archopht.116.10.1337","volume":"116","author":"Aylward G.W.","year":"1998","unstructured":"Aylward GW, Chang TS, Pautler SE, Gass JD. A long-term follow-up of choroidal osteoma.","journal-title":"Arch Ophthalmol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/archopht.123.12.1658","volume":"123","author":"Shields C.L.","year":"2005","unstructured":"Shields CL, Sun H, Demirci H, Shields JA. Factors predictive of tumor growth, tumor decalcification, choroidal neovascularization, and visual outcome in 74 eyes with choroidal osteoma.","journal-title":"Arch Ophthalmol"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/sj.eye.6701475","volume":"19","author":"Singh A.D.","year":"2005","unstructured":"Singh AD, Talbot JF, Rundle PA, Rennie IG. Choroidal neovascularization secondary to choroidal osteoma: successful treatment with photodynamic therapy.","journal-title":"Eye (Lond)"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.eye.6702016","volume":"20","author":"Shukla D.","year":"2006","unstructured":"Shukla D, Tanawade RG, Ramasamy K. Transpupillary thermotherapy for subfoveal choroidal neovascular membrane in choroidal osteoma.","journal-title":"Eye (Lond)"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archopht.121.2.273","volume":"121","author":"Foster B.S.","year":"2003","unstructured":"Foster BS, Fernandez-Suntay JP, Dryja TP. Clinicopathologic reports, case reports, and small case series: surgical removal and histopathologic findings of a subfoveal neovascular membrane associated with choroidal osteoma.","journal-title":"Arch Ophthalmol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000339624","volume":"3","author":"Wu Z.H.","year":"2012","unstructured":"Wu ZH, Wong MY, Lai TY. Long-term follow-up of intravitreal ranibizumab for the treatment of choroidal neovascularization due to choroidal osteoma.","journal-title":"Case Rep Ophthalmol"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0974-620X.169908","volume":"8","author":"Lekha T.","year":"2015","unstructured":"Lekha T, Renuka SN, Prasad HN. Anti-vascular endothelial growth factors for choroidal neovascularization secondary to choroidal osteoma: Long-term results.","journal-title":"Oman J Ophthalmol"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3341\/kjo.2012.26.6.478","volume":"26","author":"Jang J.H.","year":"2011","unstructured":"Jang JH, Kim KH, Lee SJ, Park JM. Photodynamic therapy combined with intravitreal bevacizumab in a patient with choroidal neovascularization secondary to choroidal osteoma.","journal-title":"Korean J Ophthalmol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10792-015-0059-5","volume":"35","author":"Saitta A.","year":"2015","unstructured":"Saitta A, Nicolai M, Neri P. Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab.","journal-title":"Int Ophthalmol"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/eye.2016.50","volume":"30","author":"Papastefanou V.P.","year":"2016","unstructured":"Papastefanou VP, Pefkianaki M, Al Harby L. Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma.","journal-title":"Eye (Lond)"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"210458","DOI":"10.1155\/2014\/210458","volume":"2014","author":"Mansour A.M.","year":"2014","unstructured":"Mansour AM, Arevalo J, Kahtani E. Role of intravitreal antivascular endothelial growth factor injections for choroidal neovascularization due to choroidal osteoma.","journal-title":"J Ophthalmol"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1097\/IAE.0000000000000187","volume":"34","author":"Khan M.A.","year":"2014","unstructured":"Khan MA, DeCroos FC, Storey PP. Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma.","journal-title":"Retina"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ophtha.2007.07.009","volume":"115","author":"Shields C.L.","year":"2008","unstructured":"Shields CL, Furuta M, Mashayekhi A. Clinical spectrum of choroidal nevi based on age at presentation in 3422 consecutive eyes.","journal-title":"Ophthalmology"},{"key":"ref=95","first-page":"1377","volume":"8","author":"Cavalcante M.L.","year":"2014","unstructured":"Cavalcante ML, Villegas VM, Gold AS. Treatment of vascular activity secondary to atypical choroidal nevus using intravitreal bevacizumab.","journal-title":"Clin Ophthalmol"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/IAE.0b013e31822092b7","volume":"32","author":"Chiang A.","year":"2012","unstructured":"Chiang A, Bianciotto C, Maguire JI. Intravitreal bevacizumab for choroidal neovascularization associated with choroidal nevus.","journal-title":"Retina"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0420.2005.00630.x","volume":"84","author":"Guerin E.","year":"2006","unstructured":"Guerin E, Hiscott P, Damato B. Choroidal neovascular membrane in a series of cases of malignant melanoma of the choroid.","journal-title":"Acta Ophthalmol Scand"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ajo.2010.08.040","volume":"151","author":"Lima B.R.","year":"2011","unstructured":"Lima BR, Schoenfield LR, Singh AD. The impact of intravitreal bevacizumab therapy on choroidal melanoma.","journal-title":"Am J Ophthalmol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s004170000186","volume":"238","author":"Marano F.","year":"2000","unstructured":"Marano F, Deutman AF, Leys A, Aandekerk AL. Hereditary retinal dystrophies and choroidal neovascularization.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/bjo.2004.062695","volume":"89","author":"Francis P.J.","year":"2005","unstructured":"Francis PJ, Schultz DW, Gregory AM. Genetic and phenotypic heterogeneity in pattern dystrophy.","journal-title":"Br J Ophthalmol"},{"key":"ref=101","first-page":"112","volume":"13","author":"Marmor M.F.","year":"1976","unstructured":"Marmor MF, Byers B. Pattern dystrophy of the retinal pigment epithelium.","journal-title":"Am J Ophthalmol"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00006982-200304000-00006","volume":"23","author":"Battaglia Parodi M.","year":"2003","unstructured":"Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy for choroidal neovascularization associated with pattern dystrophy.","journal-title":"Retina"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1167\/iovs.10-5237","volume":"51","author":"Parodi M.B.","year":"2010","unstructured":"Parodi MB, Iacono P, Cascavilla M. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/IAE.0b013e3182753adb","volume":"33","author":"Mimoun G.","year":"2013","unstructured":"Mimoun G, Caillaux V, Querques G. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.","journal-title":"Retina"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000336987","volume":"3","author":"Empeslidis T.","year":"2012","unstructured":"Empeslidis T, Vardarinos A, Deane J, Banerjee S. Intravitreal ranibizumab in the treatment of butterfly-shaped pattern dystrophy associated with choroidal neovascularization: a case report.","journal-title":"Case Rep Ophthalmol"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1097\/IAE.0b013e31824b32e4","volume":"32","author":"Vaclavik V.","year":"2012","unstructured":"Vaclavik V, Tran HV, Gaillard MC. Pattern dystrophy with high intrafamilial variability associated with Y141C mutation in the peripherin\/RDS gene and successful treatment of subfoveal CNV related to multifocal pattern type with anti-VEGF (ranibizumab) intravitreal injections.","journal-title":"Retina"},{"key":"ref=107","first-page":"49","volume":"11","author":"Blodi C.F.","year":"1990","unstructured":"Blodi CF, Stone EM. Best\u2019s vitelliform dystrophy.","journal-title":"Ophthalmic Paediatr Genet"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0002-9394(03)00711-6","volume":"136","author":"Andrade R.E.","year":"2003","unstructured":"Andrade RE, Farah ME, Costa RA. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease.","journal-title":"Am J Ophthalmol"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/IAE.0000000000001357","volume":"37","author":"Khan K.N.","year":"2017","unstructured":"Khan KN, Mahroo OA, Islam F. Functional and anatomical outcomes of choroidal neovascularization complicating Best1-related retinopathy.","journal-title":"Retina"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/jop.2011.0250","volume":"28","author":"Cennamo G.","year":"2012","unstructured":"Cennamo G, Cesarano I, Vecchio E. Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab.","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/ICB.0b013e31819f200e","volume":"4","author":"Brodbaker E.","year":"2010","unstructured":"Brodbaker E, Al Karmi R, Hurley B, Coupland SG. The novel use of bevacizumab and photodynamic therapy in the treatment of best disease.","journal-title":"Retin Cases Brief Rep"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaapos.2008.06.014","volume":"13","author":"Cak\u0131r M.","year":"2009","unstructured":"Cak\u0131r M, Ceki\u00e7 O, Yilmaz OF. Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease.","journal-title":"J AAPOS"},{"key":"ref=113","first-page":"1970","volume":"17","author":"Mamatha G.","year":"2011","unstructured":"Mamatha G, Umashankar V, Kasinathan N. Molecular screening of the CYP4V2 gene in Bietti crystalline dystrophy that is associated with choroidal neovascularization.","journal-title":"Mol Vis"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/APO.0000000000000209","volume":"5","author":"Ng D.S.","year":"2016","unstructured":"Ng DS, Lai TY, Ng TK, Pang CP. Genetics of Bietti crystalline dystrophy.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bjophthalmol-2016-308823","volume":"101","author":"Tanna P.","year":"2017","unstructured":"Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options.","journal-title":"Br J Ophthalmol"},{"key":"ref=116","first-page":"1","author":"Fuerst N.M.","year":"2016","unstructured":"Fuerst NM, Serrano L, Han G. Detailed functional and structural phenotype of Bietti crystalline dystrophy associated with mutations in CYP4V2 complicated by choroidal neovascularization.","journal-title":"Ophthalmic Genet"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000229030","volume":"42","author":"Quijano C.","year":"2009","unstructured":"Quijano C, Querques G, Massamba N. Type 3 choroidal neovascularization associated with fundus flavimaculatus.","journal-title":"Ophthalmic Res"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00055735-199906000-00005","volume":"10","author":"Spaide R.","year":"1999","unstructured":"Spaide R. Choroidal neovascularization in younger patients.","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0161-6420(95)30968-2","volume":"102","author":"Ho A.C.","year":"1995","unstructured":"Ho AC, Yannuzzi LA, Pisicano K, DeRosa J. The natural history of idiopathic subfoveal choroidal neovascularization.","journal-title":"Ophthalmology"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ajo.2011.07.019","volume":"153","author":"Zhang H.","year":"2012","unstructured":"Zhang H, Liu Z-L, Sun P, Gu F. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.","journal-title":"Am J Ophthalmol"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/IAE.0b013e318227ab24","volume":"32","author":"Wang F.","year":"2012","unstructured":"Wang F, Wang W, Yu S. Functional recovery after intravitreal bevacizumab treatments for idiopathic choroidal neovascularization in young adults.","journal-title":"Retina"},{"key":"ref=122","first-page":"642624","volume":"2015","author":"Rush R.B.","year":"2015","unstructured":"Rush RB, Rush SW. Evaluation of idiopathic choroidal neovascularization with indocyanine green angiography in patients undergoing bevacizumab therapy.","journal-title":"J Ophthalmol"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/jop.2016.0066","volume":"32","author":"Kim J.","year":"2016","unstructured":"Kim J, Chang Y, Kim J. Long-term outcome and recurrence of idiopathic choroidal neovascularization treated with intravitreal bevacizumab.","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=124","first-page":"382702","volume":"2014","author":"Fan C.","year":"2014","unstructured":"Fan C, Ji Q, Wang Y, Shu X, Xie J. Clinical efficacy of intravitreal ranibizumab in early and mid-idiopathic choroidal neovascularization.","journal-title":"J Ophthalmol"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/IAE.0000000000000491","volume":"35","author":"Sudhalkar A.","year":"2015","unstructured":"Sudhalkar A, Yogi R, Chhablani J. Anti-vascular endothelial growth factor therapy for na\u00efve idiopathic choroidal neovascularization: A Comparative Study.","journal-title":"Retina"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ajo.2012.10.010","volume":"155","author":"Kang H.M.","year":"2013","unstructured":"Kang HM, Koh HJ. Intravitreal anti\u2013vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.","journal-title":"Am J Ophthalmol"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/169637","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/169637\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/169637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T04:40:52Z","timestamp":1663130452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/169637\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":126,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2019,3,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190206104524","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}